Initial experience with aspirin use during robotic radical prostatectomy

Sepehr Nowfar, Ryan Kopp, Kerrin Palazzi-Churas, Ithaar H. Derweesh, Christopher J. Kane

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: New cardiology guidelines recommend antiplatelet therapy for some patients with cardiac stents. Aspirin use is relatively contraindicated during urologic surgery because of increased bleeding risk. We sought to review the outcomes of patients who continued aspirin during robot-assisted radical prostatectomy. Patients and Methods: Between October 2007 and February 2010, 249 patients underwent robot-assisted radical prostatectomy by a single surgeon. After consultation with the patients' cardiologists, 6 patients had coronary artery stents and continued aspirin perioperatively (Group 1), and 7 patients had coronary artery stents but did not continue aspirin perioperatively (Group 2). The remaining 236 patients had no coronary artery stents and did not require continued aspirin (Group 3). We analyzed our patients' preoperative characteristics, including age, prostate-specific antigen volume, and D'Amico risk, as well as operative time, blood loss, hematocrit changes, transfusion requirements, length of hospital stay, and complications. Results: We found no differences in operative time, estimated blood loss, changes in hematocrit, or length of hospital stay. No patients with any type of cardiac stent required a postoperative blood transfusion or had complications requiring more than simple anti-emetics, analgesics, or electrolyte correction. Nine patients in Group 3 required interventions for significant complications. Conclusion: Larger studies need to be performed to validate these observations.

Original languageEnglish (US)
Pages (from-to)225-229
Number of pages5
JournalJournal of Laparoendoscopic and Advanced Surgical Techniques
Volume22
Issue number3
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Robotics
Prostatectomy
Aspirin
Stents
Length of Stay
Coronary Vessels
Operative Time
Hematocrit
Antiemetics
Prostate-Specific Antigen
Cardiology
Blood Transfusion
Electrolytes
Analgesics
Referral and Consultation
Guidelines
Hemorrhage

ASJC Scopus subject areas

  • Surgery

Cite this

Initial experience with aspirin use during robotic radical prostatectomy. / Nowfar, Sepehr; Kopp, Ryan; Palazzi-Churas, Kerrin; Derweesh, Ithaar H.; Kane, Christopher J.

In: Journal of Laparoendoscopic and Advanced Surgical Techniques, Vol. 22, No. 3, 01.04.2012, p. 225-229.

Research output: Contribution to journalArticle

Nowfar, Sepehr ; Kopp, Ryan ; Palazzi-Churas, Kerrin ; Derweesh, Ithaar H. ; Kane, Christopher J. / Initial experience with aspirin use during robotic radical prostatectomy. In: Journal of Laparoendoscopic and Advanced Surgical Techniques. 2012 ; Vol. 22, No. 3. pp. 225-229.
@article{66be090d3e534f93a13db388f0d203a3,
title = "Initial experience with aspirin use during robotic radical prostatectomy",
abstract = "Background: New cardiology guidelines recommend antiplatelet therapy for some patients with cardiac stents. Aspirin use is relatively contraindicated during urologic surgery because of increased bleeding risk. We sought to review the outcomes of patients who continued aspirin during robot-assisted radical prostatectomy. Patients and Methods: Between October 2007 and February 2010, 249 patients underwent robot-assisted radical prostatectomy by a single surgeon. After consultation with the patients' cardiologists, 6 patients had coronary artery stents and continued aspirin perioperatively (Group 1), and 7 patients had coronary artery stents but did not continue aspirin perioperatively (Group 2). The remaining 236 patients had no coronary artery stents and did not require continued aspirin (Group 3). We analyzed our patients' preoperative characteristics, including age, prostate-specific antigen volume, and D'Amico risk, as well as operative time, blood loss, hematocrit changes, transfusion requirements, length of hospital stay, and complications. Results: We found no differences in operative time, estimated blood loss, changes in hematocrit, or length of hospital stay. No patients with any type of cardiac stent required a postoperative blood transfusion or had complications requiring more than simple anti-emetics, analgesics, or electrolyte correction. Nine patients in Group 3 required interventions for significant complications. Conclusion: Larger studies need to be performed to validate these observations.",
author = "Sepehr Nowfar and Ryan Kopp and Kerrin Palazzi-Churas and Derweesh, {Ithaar H.} and Kane, {Christopher J.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1089/lap.2011.0388",
language = "English (US)",
volume = "22",
pages = "225--229",
journal = "Journal of Laparoendoscopic and Advanced Surgical Techniques",
issn = "1092-6429",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Initial experience with aspirin use during robotic radical prostatectomy

AU - Nowfar, Sepehr

AU - Kopp, Ryan

AU - Palazzi-Churas, Kerrin

AU - Derweesh, Ithaar H.

AU - Kane, Christopher J.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background: New cardiology guidelines recommend antiplatelet therapy for some patients with cardiac stents. Aspirin use is relatively contraindicated during urologic surgery because of increased bleeding risk. We sought to review the outcomes of patients who continued aspirin during robot-assisted radical prostatectomy. Patients and Methods: Between October 2007 and February 2010, 249 patients underwent robot-assisted radical prostatectomy by a single surgeon. After consultation with the patients' cardiologists, 6 patients had coronary artery stents and continued aspirin perioperatively (Group 1), and 7 patients had coronary artery stents but did not continue aspirin perioperatively (Group 2). The remaining 236 patients had no coronary artery stents and did not require continued aspirin (Group 3). We analyzed our patients' preoperative characteristics, including age, prostate-specific antigen volume, and D'Amico risk, as well as operative time, blood loss, hematocrit changes, transfusion requirements, length of hospital stay, and complications. Results: We found no differences in operative time, estimated blood loss, changes in hematocrit, or length of hospital stay. No patients with any type of cardiac stent required a postoperative blood transfusion or had complications requiring more than simple anti-emetics, analgesics, or electrolyte correction. Nine patients in Group 3 required interventions for significant complications. Conclusion: Larger studies need to be performed to validate these observations.

AB - Background: New cardiology guidelines recommend antiplatelet therapy for some patients with cardiac stents. Aspirin use is relatively contraindicated during urologic surgery because of increased bleeding risk. We sought to review the outcomes of patients who continued aspirin during robot-assisted radical prostatectomy. Patients and Methods: Between October 2007 and February 2010, 249 patients underwent robot-assisted radical prostatectomy by a single surgeon. After consultation with the patients' cardiologists, 6 patients had coronary artery stents and continued aspirin perioperatively (Group 1), and 7 patients had coronary artery stents but did not continue aspirin perioperatively (Group 2). The remaining 236 patients had no coronary artery stents and did not require continued aspirin (Group 3). We analyzed our patients' preoperative characteristics, including age, prostate-specific antigen volume, and D'Amico risk, as well as operative time, blood loss, hematocrit changes, transfusion requirements, length of hospital stay, and complications. Results: We found no differences in operative time, estimated blood loss, changes in hematocrit, or length of hospital stay. No patients with any type of cardiac stent required a postoperative blood transfusion or had complications requiring more than simple anti-emetics, analgesics, or electrolyte correction. Nine patients in Group 3 required interventions for significant complications. Conclusion: Larger studies need to be performed to validate these observations.

UR - http://www.scopus.com/inward/record.url?scp=84859174912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859174912&partnerID=8YFLogxK

U2 - 10.1089/lap.2011.0388

DO - 10.1089/lap.2011.0388

M3 - Article

VL - 22

SP - 225

EP - 229

JO - Journal of Laparoendoscopic and Advanced Surgical Techniques

JF - Journal of Laparoendoscopic and Advanced Surgical Techniques

SN - 1092-6429

IS - 3

ER -